WebLyndra’s culture advantage. Lyndra’s core purpose to reinvent medicine for a healthier world, coupled with its unique values and the exceptional people who live them every … Lyndra’s visionary and determined team continues to break barriers in the quest … Lyndra’s visionary and determined team continues to break barriers in the quest … Lyndra’s revolutionary LYNX™ drug delivery platform is more than just … Lyndra is developing oral weekly levomethadone (LYN-014) for the … Lyndra believes that, for patients taking risperidone, weekly dosing (vs. daily … In 2024, Lyndra is planning to bring oral weekly risperidone (LYN-005) into … Lyndra’s LYNX™ drug delivery platform is poised to reinvent medicine for a … Web25 iun. 2024 · 包括本次融资在内,Lyndra 已经筹集了近 2.5 亿美元资金。 图丨 Lyndra Therapeutics 融资信息(来源:CB Insights) 据悉,Lyndra 的下一个重大疗法是由美国国立卫生研究院(NIH)下属单位资助,应用于阿片类药物使用障碍患者的长效、缓释左美沙酮胶囊 LYN-014。
Damien Berrard (@DamienBerrard) / Twitter
Web4 dec. 2024 · A.H. is a consultant for Lyndra Inc. Data and materials availability: All data associated with this study are in the paper or the Supplementary Materials. Supplementary Material Summary. Materials and Methods. Fig. S1. Image of gastric resident dosage form. Reference . Resources. WebThe intellectual property of Lyndra Therapeutics includes 5 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' category, according to IPqwery. … mcdowell assisted living
LYNDRA THERAPEUTICS Revenue, Growth & Competitor Profile
Web14 oct. 2024 · Lyndra Inc. Investigators. Principal Investigator: Sepehr Shakib, MD, CMAX Study record dates. These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control … WebLyndra, Inc. Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2016-05-27 Filing date 2024-05-26 Publication date 2024-01-04 Priority claimed from US201662342798P external-priority WebThe authors are coinventors on multiple provisional patent applications describing various design and manufacturing aspects of gastric resident systems. D Altreuter, T Grant, C Kruger, G Traverso, and A Bellinger have a financial interest in Lyndra, Inc, a biotechnology company developing gastric resident drug delivery systems. mcdowell arts council association